Repligen's (RGEN) "Sell (D)" Rating Reiterated at Weiss Ratings

Key Points

• Repligen's stock has been rated as a "sell" by Weiss Ratings, while it has also received varying ratings from other analysts, including an "outperform" from Evercore ISI.
• The company's recent quarterly earnings showed a missed earnings per share estimate, reporting $0.37 versus the expected $0.40, although revenue exceeded expectations with $182.37 million.
• Repligen has a consensus rating of "Moderate Buy" and a target price of $169.62, with institutional investors holding approximately 97.64% of its stock.

Repligen (NASDAQ:RGEN - Get Free Report)'s stock had its "sell (d)" rating restated by analysts at Weiss Ratings in a research note issued to investors on Wednesday,Weiss Ratings reports.

RGEN has been the subject of a number of other reports. Evercore ISI raised their target price on Repligen from $155.00 to $175.00 and gave the company an "outperform" rating in a report on Tuesday. Wall Street Zen cut Repligen from a "buy" rating to a "hold" rating in a report on Sunday, June 29th. Jefferies Financial Group lowered their target price on Repligen from $145.00 to $135.00 and set a "hold" rating for the company in a report on Friday, September 12th. Royal Bank Of Canada restated an "outperform" rating and set a $205.00 target price on shares of Repligen in a report on Tuesday, September 2nd. Finally, Wells Fargo & Company lowered their target price on Repligen from $180.00 to $175.00 and set an "overweight" rating for the company in a report on Wednesday, July 30th. One equities research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Repligen currently has a consensus rating of "Moderate Buy" and a consensus price target of $169.62.

Repligen Stock Performance

NASDAQ RGEN opened at $150.81 on Wednesday. The stock has a market cap of $8.48 billion, a PE ratio of -603.22, a P/E/G ratio of 2.69 and a beta of 1.08. The company has a current ratio of 8.59, a quick ratio of 7.32 and a debt-to-equity ratio of 0.26. Repligen has a twelve month low of $102.96 and a twelve month high of $182.52. The stock has a fifty day simple moving average of $123.96 and a 200-day simple moving average of $125.67.

Repligen (NASDAQ:RGEN - Get Free Report) last released its quarterly earnings results on Tuesday, July 29th. The biotechnology company reported $0.37 earnings per share for the quarter, missing analysts' consensus estimates of $0.40 by ($0.03). The business had revenue of $182.37 million for the quarter, compared to analysts' expectations of $174.62 million. Repligen had a positive return on equity of 4.61% and a negative net margin of 2.05%.The business's revenue for the quarter was up 14.8% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.40 earnings per share. Repligen has set its FY 2025 guidance at 1.650-1.720 EPS. Equities analysts anticipate that Repligen will post 1.72 earnings per share for the current year.

Insider Transactions at Repligen

In related news, Director Martin D. Madaus purchased 1,800 shares of Repligen stock in a transaction on Friday, August 8th. The shares were bought at an average price of $112.13 per share, with a total value of $201,834.00. Following the transaction, the director directly owned 1,800 shares of the company's stock, valued at approximately $201,834. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 1.20% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Repligen

Hedge funds and other institutional investors have recently made changes to their positions in the business. KBC Group NV raised its position in shares of Repligen by 14.9% during the 1st quarter. KBC Group NV now owns 2,544 shares of the biotechnology company's stock worth $324,000 after acquiring an additional 329 shares in the last quarter. Harvest Fund Management Co. Ltd acquired a new stake in shares of Repligen during the 1st quarter worth about $132,000. XTX Topco Ltd raised its position in shares of Repligen by 34.2% during the 1st quarter. XTX Topco Ltd now owns 12,935 shares of the biotechnology company's stock worth $1,646,000 after acquiring an additional 3,295 shares in the last quarter. GAMMA Investing LLC raised its position in shares of Repligen by 40.1% during the 1st quarter. GAMMA Investing LLC now owns 958 shares of the biotechnology company's stock worth $122,000 after acquiring an additional 274 shares in the last quarter. Finally, Dynamic Technology Lab Private Ltd raised its position in shares of Repligen by 233.6% during the 1st quarter. Dynamic Technology Lab Private Ltd now owns 9,208 shares of the biotechnology company's stock worth $1,172,000 after acquiring an additional 6,448 shares in the last quarter. Institutional investors and hedge funds own 97.64% of the company's stock.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.